- Fee assured
- Verified this account
Dr Parker is a Consultant Rheumatologist at Spire Manchester and Kellgren Centre for Rheumatology, Manchester Royal Infirmary. He offers a full private rheumatology service at Spire Manchester for both general and specialist rheumatic conditions. He specialises in the management of complex connective tissue diseases, specifically systemic lupus erythematosus (SLE) and vasculitis. He offers a full general rheumatology service managing conditions such as rheumatoid arthritis, and osteoarthritis. At Manchester Royal Infirmary he provides young adult clinics, leads the specialised rheumatology multi-disciplinary meetings and runs the rheumatology biologics service . Dr Parker acts as Principal Investigator on several early phase clinical trials in SLE, is an active researcher in the Manchester Biomedical Research Centre studying outcomes in SLE, and is Medical Director of the NIHR Manchester Clinical Research Facility at Manchester Royal Infirmary.
Areas of interest
General rheumatology; Systemic lupus erythematous; vasculitis; Connective tissue diseases; Musculoskeletal pain; Regional and Widespread Pain syndromes; Fibromyalgia; Osteoarthritis; Rheumatoid arthritis; Psoriatic and other inflammatory arthritis; Soft tissue rheumatism; Osteoporosis.
Systemic lupus erythematosus; Connective tissue diseases;
joint injections; soft tissue injections
- Colin Whitaker (billing queries)
- Avondale Medical Ltd 43-44 Pegholme Wharfebank Mills Ilkley Road Otley LS21 3JP
- 01943 660542
- 07941 173909
Current NHS consultant posts held
Kellgren Centre for Rheumatology, Manchester Royal Infirmary
Dr Parker is actively involved in research into outcomes and treatment of systemic lupus erythematosus and related connective tissue diseases. He has authored many research articles and presented his research at national and international conferences. Dr Parker is UK Chief Investigator for two Phase 2 studies in SLE and Principal Investigator on many other clinical trials in SLE and Sjogren's syndrome.
British Society of Rheumatology Outstanding Best Practice Award 2016
NICE Shared LearningAward 2017
Parker B, Bruce IN. Landmark Papers in Lupus p121-153. Landmark Papers in Rheumatology. Oxford University Press; 1st Ed.
Parker B, Bruce IN. SLE: Clinical markers, metrics, indices and clinical trials. Dubois Lupus Erythematosus and Related Syndromes 2018.
M Motwani, M Luckie, B Parker. Acute SLE and APS with cardiac complications. JACC: case reports. JACC case reports, 1:2; 2019.
Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. Barraclough M, McKie S, Parker B, Jackson A, Pemberton P, Elliott R, Bruce IN.Ann Rheum Dis. 2019 Jul;78(7):934-940
QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. Edwards N, Langford-Smith AWW, Parker BJ, Bruce IN, Reynolds JA, Alexander MY, McCarthy EM, Wilkinson FL. Lupus Sci Med. 2018 Aug 13;5(1)
Reynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E, Lee E,
Kilfeather SA, Parker B, Bruce IN. Cytokine profiling in active and quiescent SLE
reveals distinct patient subpopulations. Arthritis Res Ther. 2018 Aug 9;20(1):173.
McCarthy EM, Sutton E; Nesbit S; Parker B; et al. Short-term efficacy and safety of Rituximab therapy in refractory SLE: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology (Oxford). 2017 Jun 1;56(6):1049.
Little J, Parker B, et al. An exploration of factors associated with the use of glucocorticoids in the Systemic Lupus International Collaborating Clinics Inception Cohort. Accepted Rheumatology 2017.
Mendoza-Pinto C, Pirone C, van der Windt D, Parker B, Bruce IN. Can We Identify Who Gets Benefit or Harm from rituximab in Systemic Lupus Erythematosus? A Systematic Review. Semin Arthritis Rheum. 2017 May 5.
Mendoza-Pinto C, Pirone C, van der Windt D, Parker B, Bruce IN. Can We Identify Who Gets Benefit or Harm from Mycophenolate Mofetil in Systemic Lupus Erythematosus? A Systematic Review. Semin Arthritis Rheum. 2017 Aug;47(1):65-78.
Green D, Skeoch S, Alexander MY, Kalra PA, Parker B. Longitudinal change in endothelial microparticle count is associated with mortality in chronic kidney disease. Nephron. 2017 Jan 25.
Courses offered to GPs
I am happy to speak to GPs on any aspect of rheumatology practice, and have given talks on osteoporosis, gout and inflammatory arthritis
- FRCP Royal College of Physicians 2017
- PhD University of Manchester 2012
- MRCP Royal College of Physicians (Ed) 2005
- MBChB (with Honours) University of Liverpool 2000
Reference number 4736198
Details of entry to specialist register
- General Medical Council CCT in Rheumatology, 2013
Affiliations / memberships
General Medical Council
Royal College of Physicians
Medical Defence Union
British Society for Rheumatology
- Spire Manchester
- 16:30 - 20:30
- 0161 447 6600
- Spire Manchester
- 16:00 - 19:00
- 0161 447 6600
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
myself via my PA or hospital switchboard